The cancer care platform developer secured funding in a series D round co-led by Merck Global Health Innovation Fund and backed by LabCorp.

Pharmaceutical firm Merck & Co has co-led a $26m series D round for US-based cancer care technology provider Navigating Cancer through its Merck Global Health Innovation (GHI) Fund.

The round was co-led by TT Capital Partners, part of healthcare merchant bank TripleTree, and included laboratory services provider LabCorp, Orix Growth Capital, Rustic Canyon Partners and BrightEdge, a fund overseen by the American Cancer Society.

Navigating Cancer’s Patient Relationship Management software helps care providers more effectively engage and communicate with cancer patients, and the proceeds from the series D round will be used to strengthen the platform.

Merck GHI led the company’s last round, a $10m series C in 2015 that also featured Orix Healthcare Capital and Rustic Canyon Partners.

Rustic Canyon provided $2m of funding for Navigating Cancer in 2009 and joined an undisclosed angel investor to add $3m in a 2011 series A round. It received $2.3m in debt financing from Western Technology Investment the following year.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.